Microparticles and vascular dysfunction in obstructive sleep apnoea

European Respiratory Journal

Volumn 44, Issue 1, 2014, Pages 207-216

  Trzepizur, Wojciech ^a,b   Martinez, Maria Carmen ^a   Priou, Pascaline ^a,b  

^a UNIVERSITÉ D'ANGERS   (France)

^b ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACID CITRATE DEXTROSE; BETA3 INTEGRIN; C REACTIVE PROTEIN; CD11B ANTIGEN; CD146 ANTIGEN; CD31 ANTIGEN; CD45 ANTIGEN; CD66B ANTIGEN; CELL ADHESION MOLECULE; CITRIC ACID; EDETIC ACID; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IB ALPHA; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 8; L SELECTIN; LYMPHOCYTE ANTIGEN; PADGEM PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE;

ATHEROGENESIS; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL MICROPARTICLE; HUMAN; LEUKOCYTE MICROPARTICLE; LIPID PEROXIDATION; MEMBRANE MICROPARTICLE; NONHUMAN; OXIDATIVE STRESS; PLATELET MICROPARTICLE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SLEEP DISORDERED BREATHING; VASCULAR DISEASE; VASCULITIS; ANIMAL; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL MEMBRANE; INFLAMMATION; LEUKOCYTE; METABOLISM; MOUSE; PATHOPHYSIOLOGY; PHENOTYPE; RISK FACTOR; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

ANIMALS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CELL MEMBRANE; CELL-DERIVED MICROPARTICLES; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; LEUKOCYTES; MICE; OXIDATIVE STRESS; PHENOTYPE; RISK FACTORS; SLEEP APNEA, OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 84903852646     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00197413     Document Type: Review

References (87)

1. Marin JM, Carrizo SJ, Vicente E, et al. Long-term cardiovascular outcomes in men with obstructive sleep apnoeahypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005; 365: 1046-1053.
2. Marshall NS, Wong KK, Liu PY, et al. Sleep apnea as an independent risk factor for all-cause mortality: the Busselton Health Study. Sleep 2008; 31: 1079-1085.
3. Punjabi NM, Caffo BS, Goodwin JL, et al. Sleep-disordered breathing and mortality: a prospective cohort study. PLoS Med 2009; 6: e1000132.
4. Gottlieb DJ, Yenokyan G, Newman AB, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the Sleep Heart Health Study. Circulation 2010; 122: 352-360.
5. Redline S, Yenokyan G, Gottlieb DJ, et al. Obstructive sleep apnea-hypopnea and incident stroke: the Sleep Heart Health Study. Am J Respir Crit Care Med 2010; 182: 269-277.
6. Chami HA, Devereux RB, Gottdiener JS, et al. Left ventricular morphology and systolic function in sleepdisordered breathing: the Sleep Heart Health Study. Circulation 2008; 117: 2599-2607.
7. Wachter R, Luthje L, Klemmstein D, et al. Impact of obstructive sleep apnoea on diastolic function. Eur Respir J 2013; 41: 376-383.
8. Rossi VA, Stradling JR, KohlerM. Effects of obstructive sleep apnoea on heart rhythm. Eur Respir J 2013; 41: 1439-1451.
9. Savransky V, Nanayakkara A, Li J, et al. Chronic intermittent hypoxia induces atherosclerosis. Am J Respir Crit Care Med 2007; 175: 1290-1297.
10. Jun J, Reinke C, Bedja D, et al. Effect of intermittent hypoxia on atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 2010; 209: 381-386.
11. Li J, Savransky V, Nanayakkara A, et al. Hyperlipidemia and lipid peroxidation are dependent on the severity of chronic intermittent hypoxia. J Appl Physiol 2007; 102: 557-563.
12. Trzepizur W, Le Vaillant M, Meslier N, et al. Independent association between nocturnal intermittent hypoxemia and metabolic dyslipidemia. Chest 2013; 143: 1584-1589.
13. Iiyori N, Alonso LC, Li J, et al. Intermittent hypoxia causes insulin resistance in lean mice independent of autonomic activity. Am J Respir Crit Care Med 2007; 175: 851-857.
14. Dematteis M, Julien C, Guillermet C, et al. Intermittent hypoxia induces early functional cardiovascular remodeling in mice. Am J Respir Crit Care Med 2008; 177: 227-235.
15. Camaioni C, Gustapane M, Cialdella P, et al. Microparticles and microRNAs: new players in the complex field of coagulation. Intern Emerg Med 2013; 8: 291-296.
16. Rautou PE, Leroyer AS, Ramkhelawon B, et al. Microparticles from human atherosclerotic plaques promote endothelial ICAM-1-dependent monocyte adhesion and transendothelial migration. Circ Res 2011; 108: 335-343.
17. Faille D, El-Assaad F, Mitchell AJ, et al. Endocytosis and intracellular processing of platelet microparticles by brain endothelial cells. J Cell Mol Med 2012; 16: 1731-1738.
18. Quesenberry PJ, Aliotta JM. Cellular phenotype switching and microvesicles. Adv Drug Deliv Rev 2010; 62: 1141-1148.
19. Tual-Chalot S, Leonetti D, Andriantsitohaina R, et al. Microvesicles: intercellular vectors of biological messages. Mol Interv 2011; 11: 88-94.
20. Martinez MC, Tual-Chalot S, Leonetti D, et al. Microparticles: targets and tools in cardiovascular disease. Trends Pharmacol Sci 2011; 32: 659-665.
21. Martinez MC, Andriantsitohaina R. Microparticles in angiogenesis: therapeutic potential. Circ Res 2011; 109: 110-119.
22. Andriantsitohaina R, Gaceb A, Vergori L, et al. Microparticles as regulators of cardiovascular inflammation. Trends Cardiovasc Med 2012; 22: 88-92.
23. Owens AP 3rd, Mackman N. Microparticles in hemostasis and thrombosis. Circ Res 2011; 108: 1284-1297.
24. Augustine D, Ayers LV, Lima E, et al. Dynamic Release and Clearance of Circulating Microparticles During Cardiac Stress. Circ Res 2014; 114: 109-113.
25. Mostefai HA, Meziani F, Mastronardi ML, et al. Circulating microparticles from patients with septic shock exert protective role in vascular function. Am J Respir Crit Care Med 2008; 178: 1148-1155.
26. Perez-Casal M, Thompson V, Downey C, et al. The clinical and functional relevance of microparticles induced by activated protein C treatment in sepsis. Crit Care 2011; 15: R195.
27. Amabile N, Boulanger CM. Circulating microparticle levels in patients with coronary artery disease: a new indicator of vulnerability. Eur Heart J 2011; 32: 1958-1960.
28. Morel O, Pereira B, Averous G, et al. Increased levels of procoagulant tissue factor-bearing microparticles within the occluded coronary artery of patients with ST-segment elevation myocardial infarction: role of endothelial damage and leukocyte activation. Atherosclerosis 2009; 204: 636-641.
29. Boulanger CM. Microparticles, vascular function and hypertension. Curr Opin Nephrol Hypertens 2010; 19: 177-180.
30. Nomura S. Dynamic role of microparticles in type 2 diabetes mellitus. Curr Diabetes Rev 2009; 5: 245-251.
31. McVey M, Tabuchi A, Kuebler WM. Microparticles and acute lung injury. Am J Physiol Lung Cell Mol Physiol 2012; 303: L364-L381.
32. Amabile N, Guignabert C, Montani D, et al. Cellular microparticles in the pathogenesis of pulmonary hypertension. Eur Respir J 2013; 42: 272-279.
33. Chironi G, Simon A, Hugel B, et al. Circulating leukocyte-derived microparticles predict subclinical atherosclerosis burden in asymptomatic subjects. Arterioscler Thromb Vasc Biol 2006; 26: 2775-2780.
34. Lee ST, Chu K, Jung KH, et al. Circulating CD62E+ microparticles and cardiovascular outcomes. PLoS One 2012; 7: e35713.
35. Ferreira AC, Peter AA, Mendez AJ, et al. Postprandial hypertriglyceridemia increases circulating levels of endothelial cell microparticles. Circulation 2004; 110: 3599-3603.
36. Chaar V, Romana M, Tripette J, et al. Effect of strenuous physical exercise on circulating cell-derived microparticles. Clin Hemorheol Microcirc 2011; 47: 15-25.
37. Ayers L, Kohler M, Harrison P, et al. Measurement of circulating cell-derived microparticles by flow cytometry: sources of variability within the assay. Thromb Res 2011; 127: 370-377.
38. Dey-Hazra E, Hertel B, Kirsch T, et al. Detection of circulating microparticles by flow cytometry: influence of centrifugation, filtration of buffer, and freezing. Vasc Health Risk Manag 2010; 6: 1125-1133.
39. Lacroix R, Judicone C, Poncelet P, et al. Impact of pre-analytical parameters on the measurement of circulating microparticles: towards standardization of protocol. J Thromb Haemost 2012; 10: 437-446.
40. Jayachandran M, Miller VM, Heit JA, et al. Methodology for isolation, identification and characterization of microvesicles in peripheral blood. J Immunol Methods 2012; 375: 207-214.
41. Stagnara J, Garnache Ottou F, Angelot F, et al Correlation between platelet-derived microparticle enumeration by flow cytometry and phospholipid-dependent procoagulant activity in microparticles: the centrifugation step matters! Thromb Haemost 2012; 107: 1185-1187.
42. Lacroix R, Judicone C, Mooberry M, et al. Standardization of pre-analytical variables in plasma microparticle determination: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemost 2013; 11: 1190-1193.
43. Jimenez JJ, Jy W, Mauro LM, et al. Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis. Thromb Res 2003; 109: 175-180.
44. Bernal-Mizrachi L, Jy W, Jimenez JJ, et al. High levels of circulating endothelial microparticles in patients with acute coronary syndromes. Am Heart J 2003; 145: 962-970.
45. Horstman LL, Jy W, Jimenez JJ, et al. New horizons in the analysis of circulating cell-derived microparticles. Keio J Med 2004; 53: 210-230.
46. Wang W, Singh S, Zeng DL, et al. Antibody structure, instability, and formulation. J Pharm Sci 2007; 96: 1-26.
47. Aass HC, Ovstebo R, Troseid AM, et al. Fluorescent particles in the antibody solution result in false TF- and CD14- positive microparticles in flow cytometric analysis. Cytometry A 2011; 79: 990-999.
48. Lacroix R, Robert S, Poncelet P, et al. Overcoming limitations of microparticle measurement by flow cytometry. Semin Thromb Hemost 2012; 36: 807-818.
49. Geiser T, Buck F, Meyer BJ, et al. In vivo platelet activation is increased during sleep in patients with obstructive sleep apnea syndrome. Respiration 2002; 69: 229-234.
50. Jelic S, Lederer DJ, Adams T, et al. Endothelial repair capacity and apoptosis are inversely related in obstructive sleep apnea. Vasc Health Risk Manag 2009; 5: 909-920.
51. Ayers L, Ferry B, Craig S, et al. Circulating cell-derived microparticles in patients with minimally symptomatic obstructive sleep apnoea. Eur Respir J 2009; 33: 574-580.
52. Priou P, Gagnadoux F, Tesse A, et al. Endothelial dysfunction and circulating microparticles from patients with obstructive sleep apnea. Am J Pathol 2010; 177: 974-983.
53. Yun CH, Jung KH, Chu K, et al. Increased circulating endothelial microparticles and carotid atherosclerosis in obstructive sleep apnea. J Clin Neurol 2010; 6: 89-98.
54. Kim J, Bhattacharjee R, Kheirandish-Gozal L, et al. Circulating microparticles in children with sleep disordered breathing. Chest 2011; 140: 408-417.
55. Maruyama K, Morishita E, Sekiya A, et al. Plasma levels of platelet-derived microparticles in patients with obstructive sleep apnea syndrome. J Atheroscler Thromb 2012; 19: 98-104.
56. Trzepizur W, Priou P, Paris A, et al. Nocturnal release of leukocyte-derived microparticles in males with obstructive sleep apnoea. Eur Respir J 2011; 37: 1293-1295.
57. Ayers L, Stoewhas AC, Ferry B, et al. Elevated levels of endothelial cell-derived microparticles following short-term withdrawal of continuous positive airway pressure in patients with obstructive sleep apnea: data from a randomized controlled trial. Respiration 2013; 85: 478-485.
58. Agouni A, Ducluzeau PH, Benameur T, et al. Microparticles from patients with metabolic syndrome induce vascular hypo-reactivity via Fas/Fas-ligand pathway in mice. PLoS One 2011; 6: e27809.
59. Nomura S, Tandon NN, Nakamura T, et al. High-shear-stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells. Atherosclerosis 2001; 158: 277-287.
60. Lee YJ, Jy W, Horstman LL, et al. Elevated platelet microparticles in transient ischemic attacks, lacunar infarcts, and multiinfarct dementias. Thromb Res 1993; 72: 295-304.
61. Geiser T, Sturzenegger M, Genewein U, et al. Mechanisms of cerebrovascular events as assessed by procoagulant activity, cerebral microemboli, and platelet microparticles in patients with prosthetic heart valves. Stroke 1998; 29: 1770-1777.
62. Liak C, Fitzpatrick M. Coagulability in obstructive sleep apnea. Can Respir J 2011; 18: 338-348.
63. Angelillo-Scherrer A. Leukocyte-derived microparticles in vascular homeostasis. Circ Res 2012; 110: 356-369.
64. Nomura S, Kanazawa S, Fukuhara S. Effects of efonidipine on platelet and monocyte activation markers in hypertensive patients with and without type 2 diabetes mellitus. J Hum Hypertens 2002; 16: 539-547.
65. Montserrat JM, Garcia-Rio F, Barbe F. Diagnostic and therapeutic approach to nonsleepy apnea. Am J Respir Crit Care Med 2007; 176: 6-9.
66. Barbe F, Mayoralas LR, Duran J, et al. Treatment with continuous positive airway pressure is not effective in patients with sleep apnea but no daytime sleepiness. a randomized, controlled trial. Ann Intern Med 2001; 134: 1015-1023.
67. Robinson GV, Smith DM, Langford BA, et al. Continuous positive airway pressure does not reduce blood pressure in nonsleepy hypertensive OSA patients. Eur Respir J 2006; 27: 1229-1235.
68. Hogg N, Browning J, Howard T, et al. Apoptosis in vascular endothelial cells caused by serum deprivation, oxidative stress and transforming growth factor-b. Endothelium 1999; 7: 35-49.
69. Ryan S, Taylor CT, McNicholas WT. Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation 2005; 112: 2660-2667.
70. Kohler M, Stoewhas AC, Ayers L, et al. Effects of continuous positive airway pressure therapy withdrawal in patients with obstructive sleep apnea: a randomized controlled trial. Am J Respir Crit Care Med 2011; 184: 1192-1199.
71. Cross MD, Mills NL, Al-Abri M, et al. Continuous positive airway pressure improves vascular function in obstructive sleep apnoea/hypopnoea syndrome: a randomised controlled trial. Thorax 2008; 63: 578-583.
72. Drager LF, Polotsky VY, Lorenzi-Filho G. Obstructive sleep apnea: an emerging risk factor for atherosclerosis. Chest 2011; 140: 534-542.
73. Martin S, Tesse A, Hugel B, et al. Shed membrane particles from T lymphocytes impair endothelial function and regulate endothelial protein expression. Circulation 2004; 109: 1653-1659.
74. Mostefai HA, Agouni A, Carusio N, et al. Phosphatidylinositol 3-kinase and xanthine oxidase regulate nitric oxide and reactive oxygen species productions by apoptotic lymphocyte microparticles in endothelial cells. J Immunol 2008; 180: 5028-5035.
75. Tual-Chalot S, Fatoumata K, Priou P, et al. Circulating microparticles from patients with obstructive sleep apnea enhance vascular contraction: mandatory role of the endothelium. Am J Pathol 2012; 181: 1473-1482.
76. Shamsuzzaman AS, Winnicki M, Lanfranchi P, et al. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 2002; 105: 2462-2464.
77. Drager LF, Lopes HF, Maki-Nunes C, et al. The impact of obstructive sleep apnea on metabolic and inflammatory markers in consecutive patients with metabolic syndrome. PLoS One 2010; 5: e12065.
78. Ohga E, Tomita T, Wada H, et al. Effects of obstructive sleep apnea on circulating ICAM-1, IL-8, and MCP-1. J Appl Physiol 2003; 94: 179-184.
79. Dyugovskaya L, Polyakov A, Lavie P, et al. Delayed neutrophil apoptosis in patients with sleep apnea. Am J Respir Crit Care Med 2008; 177: 544-554.
80. MacKenzie A, Wilson HL, Kiss-Toth E, et al. Rapid secretion of interleukin-1b by microvesicle shedding. Immunity 2001; 15: 825-835.
81. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 84: 1381-1478.
82. Savransky V, Jun J, Li J, et al. Dyslipidemia and atherosclerosis induced by chronic intermittent hypoxia are attenuated by deficiency of stearoyl coenzyme A desaturase. Circ Res 2008; 103: 1173-1180.
83. Jun J, Savransky V, Nanayakkara A, et al. Intermittent hypoxia has organ-specific effects on oxidative stress. Am J Physiol Regul Integr Comp Physiol 2008; 295: R1274-R1281.
84. Tan KC, Chow WS, Lam JC, et al. HDL dysfunction in obstructive sleep apnea. Atherosclerosis 2006; 184: 377-382.
85. Jelic S, Padeletti M, Kawut SM, et al. Inflammation, oxidative stress, and repair capacity of the vascular endothelium in obstructive sleep apnea. Circulation 2008; 117: 2270-2278.
86. Lavie L, Vishnevsky A, Lavie P. Evidence for lipid peroxidation in obstructive sleep apnea. Sleep 2004; 27: 123-128.
87. Agouni A, Lagrue-Lak-Hal AH, Ducluzeau PH, et al. Endothelial dysfunction caused by circulating microparticles from patients with metabolic syndrome. Am J Pathol 2008; 173: 1210-1219.